Transdermal Patch
Results positive in study of PDE4 inhibitor for cognitive impairment in schizophrenia
A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy volunteers of a novel PDE4 inhibitor being developed to treat those with cognitive impairment associated with schizophrenia.
Weekly patch available for patients with Alzheimer’s
Corium Inc. announced that Adlarity transdermal treatment is available to prescribe in the U.S. for patients with Alzheimer’s.
Weekly transdermal donepezil equally effective, more tolerable than daily oral therapy
SAN DIEGO — A once-weekly dose of transdermal donepezil proved a safe and effective equivalent to a daily dose of oral donepezil for Alzheimer’s-related dementia, per a presenter at the Alzheimer’s Association International Conference.
FDA approves transdermal patch to treat Alzheimer’s-related dementia
Biopharmaceutical company Corium announced that the FDA has approved Adlarity to treat patients with mild, moderate or severe dementia associated with Alzheimer’s disease, according to a press release.
FDA approves asenapine transdermal patch for schizophrenia
The FDA has approved the first asenapine transdermal system for the treatment of adults with schizophrenia, according to a press release from the agent’s manufacturer.
Radius begins phase 3 study for wearable osteoporosis drug
Radius Health has initiated enrollment for a phase 3 clinical trial to assess the safety and efficacy of a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture, the company announced in a press release.